Page 1

OPKO OPKO Health Reports 2021 Second Quarter Business Highlights and Financial Results July 29 , 2021 Conference call begins at 4:30 p.m. Eastern time today MIAMI , July 29 , 2021 ( GLOBE NEWSWIRE ) -- OPKO Health , Inc. ( NASDAQ : OPK ) reports business highlights and financial results for the three months ended June 30 , 2021 . Business Highlights • BioReference Laboratories ( BRL ) test volume increased 32 % compared with the second quarter of 2020. During the second quarter of 2021 , BRL processed approximately 2.8 million COVID - 19 PCR tests and has current capacity to process more than 100,000 PCR tests per day . In addition , during the quarter BRL performed approximately 132,000 COVID - 19 serology tests to measure SARS - CoV - 2 antibody levels and currently has significant additional capacity . In June 2021 , BRL announced a COVID - 19 custom testing program for U.S. - based crew and guests who cruise with Royal Caribbean Group , helping provide a safe environment for travelers and crew members . In April 2021 , BRL announced a COVID 19 testing agreement for players and staff , stadium employees and league staff for the 2021 Major League Baseball season and the renewal of a similar agreement for the 2021 Major League Soccer season and 2021-2022 National Football League season . Also , BRL announced the appointment of Katherine Stueland as President and Chief Executive Officer of GeneDx , Inc. , its global genomics subsidiary . Ms. Stueland joined GeneDx from Invitae Corporation , where she served most recently as Chief Commercial Officer . • Executed agreement with Nicoya Therapeutics for the development and commercialization of RAYALDEE® in Greater China . OPKO entered into an agreement with Nicoya Macau Limited , an affiliate of Nicoya Therapeutics ( Nicoya ) , for the development and commercialization in Greater China including mainland China , Hong Kong , Macau and Taiwan of RAYALDEE for the treatment of secondary hyperparathyroidism ( SHPT ) in patients with stage 3 or 4 chronic kidney disease ( CKD ) . OPKO received an upfront payment of $ 5 million and is entitled to receive an additional $ 5 million payment upon the earlier of the 12 - month anniversary of the agreement or Nicoya achieving a certain predetermined development milestone . In addition , OPKO will be eligible to receive up to $ 115 million upon the achievement of certain development , regulatory and sales - based milestones . Nicoya will pay OPKO tiered , double - digit royalties on product sales and will be responsible for regulatory approvals and commercial activities pertaining to RAYALDEE in their territory .